Literature DB >> 30190372

Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?

Michael L Cheng1,2, Geoffrey R Oxnard3,2.   

Abstract

Patients with EGFR-mutant non-small cell lung cancer achieve variable benefit from targeted therapy, and biomarkers to predict degree of benefit are not in clinical use. EGFR-mutant cancers with high tumor mutational burden demonstrate poorer outcomes on EGFR-targeted therapy. Investigation into the mechanisms underlying this intriguing association is needed.See related article by Offin et al., p. 1063. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30190372      PMCID： PMC6359945          DOI： 10.1158/1078-0432.CCR-18-2368

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  6 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  The cellular origins of drug resistance in cancer.

Authors:  Geoffrey R Oxnard
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

3.  Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Authors:  Matteo Canale; Elisabetta Petracci; Angelo Delmonte; Elisa Chiadini; Claudio Dazzi; Maximilian Papi; Laura Capelli; Claudia Casanova; Nicoletta De Luigi; Marita Mariotti; Alessandro Gamboni; Rita Chiari; Chiara Bennati; Daniele Calistri; Vienna Ludovini; Lucio Crinò; Dino Amadori; Paola Ulivi
Journal:  Clin Cancer Res       Date:  2016-10-25       Impact factor: 12.531

4.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Authors:  Hira Rizvi; Francisco Sanchez-Vega; Konnor La; Walid Chatila; Philip Jonsson; Darragh Halpenny; Andrew Plodkowski; Niamh Long; Jennifer L Sauter; Natasha Rekhtman; Travis Hollmann; Kurt A Schalper; Justin F Gainor; Ronglai Shen; Ai Ni; Kathryn C Arbour; Taha Merghoub; Jedd Wolchok; Alexandra Snyder; Jamie E Chaft; Mark G Kris; Charles M Rudin; Nicholas D Socci; Michael F Berger; Barry S Taylor; Ahmet Zehir; David B Solit; Maria E Arcila; Marc Ladanyi; Gregory J Riely; Nikolaus Schultz; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2018-01-16       Impact factor: 44.544

5.  Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

Authors:  Michael Offin; Hira Rizvi; Megan Tenet; Andy Ni; Francisco Sanchez-Vega; Bob T Li; Alexander Drilon; Mark G Kris; Charles M Rudin; Nikolaus Schultz; Maria E Arcila; Marc Ladanyi; Gregory J Riely; Helena Yu; Matthew D Hellmann
Journal:  Clin Cancer Res       Date:  2018-07-25       Impact factor: 12.531

6.  Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Authors:  Geoffrey R Oxnard; Yuebi Hu; Kathryn F Mileham; Hatim Husain; Daniel B Costa; Philip Tracy; Nora Feeney; Lynette M Sholl; Suzanne E Dahlberg; Amanda J Redig; David J Kwiatkowski; Michael S Rabin; Cloud P Paweletz; Kenneth S Thress; Pasi A Jänne
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777
  6 in total
  6 in total

1.  Depression and inflammation among epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer patients.

Authors:  Daniel C McFarland; Devika R Jutagir; Barry Rosenfeld; William Pirl; Andrew H Miller; William Breitbart; Christian Nelson
Journal:  Psychooncology       Date:  2019-05-15       Impact factor: 3.894

2.  Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation.

Authors:  Daniel C McFarland; Devika R Jutagir; Andrew H Miller; William Breitbart; Christian Nelson; Barry Rosenfeld
Journal:  J Natl Compr Canc Netw       Date:  2020-04       Impact factor: 11.908

3.  Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.

Authors:  Qitong Chen; Dengjie Ouyang; Munawar Anwar; Ning Xie; Shouman Wang; Peizhi Fan; Liyuan Qian; Gannong Chen; Enxiang Zhou; Lei Guo; Xiaowen Gu; Boni Ding; Xiaohong Yang; Liping Liu; Chao Deng; Zhi Xiao; Jing Li; Yunqi Wang; Shan Zeng; Jinhui Hu; Wei Zhou; Bo Qiu; Zhongming Wang; Jie Weng; Mingwen Liu; Yi Li; Tiegang Tang; Jianguo Wang; Hui Zhang; Bin Dai; Wuping Tang; Tao Wu; Maoliang Xiao; Xiantao Li; Hailong Liu; Lai Li; Wenjun Yi; Quchang Ouyang
Journal:  Front Oncol       Date:  2020-05-25       Impact factor: 6.244

4.  Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations.

Authors:  Yudie Yang; Xia Zhang; Yajie Gao; Yan Dong; Di Wang; Yanping Huang; Tianhao Qu; Buqun Fan; Qizheng Li; Chunxia Zhang; Xiaonan Cui; Bin Zhang
Journal:  Oncol Res       Date:  2022-03-02       Impact factor: 4.938

5.  [Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].

Authors:  Hanfei Guo; Rilan Bai; Jiuwei Cui
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-02-20

6.  Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France).

Authors:  Sandra Lassalle; Véronique Hofman; Simon Heeke; Jonathan Benzaquen; Elodie Long; Michel Poudenx; Elisabeth Lantéri; Jacques Boutros; Virginie Tanga; Katia Zahaf; Salomé Lalvée; Virginie Lespinet; Olivier Bordone; Jean-Marc Félix; Christelle Bonnetaud; Charles Marquette; Marius Ilie; Paul Hofman
Journal:  Cancers (Basel)       Date:  2020-04-13       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.